{"result": "(\"entity\"<|>MARTIN L<|>PERSON<|>Martin L is an author who contributed to the study on cancer cachexia and its implications on muscle mass and prognosis in cancer patients.)\n##\n(\"entity\"<|>BIRDSELL L<|>PERSON<|>Birdsell L is a co-author of the study discussing the impact of muscle depletion on cancer prognosis.)\n##\n(\"entity\"<|>MACDONALD N<|>PERSON<|>Macdonald N is a researcher involved in the study of cancer cachexia and its effects on patients.)\n##\n(\"entity\"<|>REIMAN T<|>PERSON<|>Reiman T is one of the authors who studied the relationship between muscle mass and cancer outcomes.)\n##\n(\"entity\"<|>CLANDININ MT<|>PERSON<|>Clandinin MT is a contributor to the research on cancer cachexia and nutritional support.)\n##\n(\"entity\"<|>MCCARGAR LJ<|>PERSON<|>McCargar LJ is a researcher who co-authored the study on cancer cachexia.)\n##\n(\"entity\"<|>CANCER CACHEXIA<|>EVENT<|>Cancer cachexia is a syndrome characterized by severe body weight, muscle mass loss, and metabolic changes in cancer patients.)\n##\n(\"entity\"<|>NUTRITIONAL SUPPORT<|>EVENT<|>Nutritional support refers to the treatment strategies aimed at maintaining or improving muscle mass and overall health in cancer patients.)\n##\n(\"relationship\"<|>MARTIN L<|>CANCER CACHEXIA<|>Martin L contributed to the research on cancer cachexia, highlighting its impact on muscle mass and prognosis.<|>8)\n##\n(\"relationship\"<|>BIRDSELL L<|>CANCER CACHEXIA<|>Birdsell L's research focuses on the effects of muscle depletion in cancer patients, contributing to the understanding of cancer cachexia.<|>8)\n##\n(\"relationship\"<|>MACDONALD N<|>CANCER CACHEXIA<|>Macdonald N's work is related to the study of cancer cachexia and its implications for patient care.<|>8)\n##\n(\"relationship\"<|>REIMAN T<|>CANCER CACHEXIA<|>Reiman T's research is part of the broader study on cancer cachexia and its effects on patients' health.<|>8)\n##\n(\"relationship\"<|>CLANDININ MT<|>CANCER CACHEXIA<|>Clandinin MT's contributions to the study of cancer cachexia focus on nutritional aspects and patient outcomes.<|>8)\n##\n(\"relationship\"<|>MCCARGAR LJ<|>CANCER CACHEXIA<|>McCargar LJ's research is integral to understanding the implications of cancer cachexia on patient nutrition and health.<|>8)\n##\n(\"relationship\"<|>NUTRITIONAL SUPPORT<|>CANCER CACHEXIA<|>Nutritional support is a critical intervention for managing cancer cachexia and improving patient outcomes.<|>9)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: la que predice el riesgo de alteración de la capacidad física, complicaciones postoperatorias, toxicidad de la quimioterapia\n---\nTema 40. Valoración y soporte nutricional en el paciente oncológico 637\n\n| IMC (Kg/m²) |    |    |    |    |\n|--------------|----|----|----|----|\n|              | 28 | 25 | 22 | 20 |\n| Pérdida de peso (%) 0 | 0 | 1 | 1 | 3 |\n| 2,5 | 1 | 2 | 2 | 3 |\n| 6 | 2 | 3 | 3 | 4 |\n| 11 | 3 | 3 | 4 | 4 |\n| 15 | 3 | 4 | 4 | 4 |\n\nAdaptado de Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 2013; 31:1539-47.\n\nFigura 1. Esquema grados (grado 0-4) para predecir la supervivencia en pacientes con cáncer avanzado. Tanto el IMC como la pérdida ponderal condicionan el pronóstico de forma independiente. (0: mejor, 4: peor pronóstico). (p < 0,001; ajustado por edad, sexo, localización de la enfermedad, estadío y estado funcional).\n\ny mortalidad³. Un valor generalmente aceptado para pérdida grave de masa muscular es un valor absoluto de masa muscular por debajo del percentil 5. Esto puede ser evaluado según lo siguiente: área muscular media-superior del brazo por antropometría (varones < 32 cm², mujeres < 18 cm²), índice de músculo esquelético apendicular determinado por absorciometría dual de rayos X (varones < 7,26 kg/m², mujeres < 5,45 kg/m²), índice músculo esquelético lumbar determinado por CT oncológico (varones < 55 cm²/m², mujeres < 39 cm²/m²), índice de masa libre de grasa corporal sin hueso determinado por bioimpedanciometría (varones < 14,6 kg/m², mujeres < 11,4 kg/m²). La masa muscular por debajo de estos valores está fuertemente asociada con mortalidad en pacientes con cáncer, así como complicaciones de la cirugía del cáncer y toxicidad dosis limitante durante el tratamiento oncológico sistémico. Los objetivos del tratamiento metabólico y nutricional por tanto, deberían enfatizar de forma considerable el mantenimiento o la ganancia de masa muscular. Dado que la capacidad física y el estado funcional están alterados en muchos pacientes con cáncer y esto a menudo se acompaña de una mayor pérdida de masa muscular, se recomienda la combinación de tratamiento nutricional y actividad física.\n\n3. El síndrome de inflamación sistémica es frecuente en los pacientes con cáncer. Esto puede variar en importancia pero afecta a todas las vías metabólicas relevantes incluyendo:\n   • Metabolismo proteico: la inflamación sistémica se asocia con alteración del turnover proteico, pérdida de grasa y masa muscular y aumento en la producción de proteínas de fase aguda.\n\n• Metabolismo de carbohidratos: la inflamación sistémica se asocia con frecuencia con resistencia a la insulina y alteración de la tolerancia a la glucosa.\n• Metabolismo lipídico: la capacidad para oxidación de lípidos se mantiene o está aumentada en pacientes con cáncer y especialmente en presencia de pérdida de peso.\n\nEstas alteraciones en conjunto suelen mejorar con el tratamiento nutricional, el manejo médico del dolor y los síntomas, los agentes farmacológicos y la actividad física. La eficacia del tratamiento nutricional puede optimizarse sinérgicamente con actividad física y/o fármacos (por ejemplo, para promover el anabolismo muscular o control de la inflamación o resistencia a la insulina).\n\n2.2.2. Causas de desnutrición relacionadas con los tratamientos oncológicos\n\nCirugía. La cirugía realizada en la mayor parte de estos enfermos contribuye de forma importante al deterioro del estado nutricional de los mismos, y la capacidad para que esta pueda ser causa de desnutrición está en función de la localización del tumor, el grado de agresión de la cirugía, el período de ayuno postoperatorio, las complicaciones y las secuelas a largo plazo. La cirugía dificulta la alimentación durante el período postoperatorio que, junto al incremento de las necesidades nutricionales por el estrés metabólico que produce y al aumento de las demandas que conlleva la cicatrización de los tejidos, favorecen la desnutrición en este tipo de pacientes, que en\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}